Real World One-Year Outcomes of Treatment Intensive Neovascular Age Related Macular Degeneration switched to Faricimab
Sing Yue Sim,Evangelia Chalkiadaki,Georgios Koutsocheras,Luke Nicholson,Sobha Sivaprasad,Praveen J Patel,Senthil Selvam,Bishwanath Pal,Pearse A Keane,Bhairavi Bhatia,Robin Hamilton,Moorfields Medical Retina Injection Service,Abison Logeswaran,Adnan Tufail,Avinash Gurbaxani,Catherine Egan,David Bessant,Dhanes Thomas,Heng Ling,Josef Huemer,Khadijah Basheer,Konstantinos Balaskas,Konstantinos Bouras,Lyndon Da Cruz,Mythili Natkunarajah,Narciss Okhravi,Niaz Islam,Parul Desai,Peter Addison,Ranjan Rajendram,Simona Esposti,Tjebo Heeren,Waheeda Rahman,Yasir Khan,Zoe Ockrim,Zubin Saihan
DOI: https://doi.org/10.1016/j.oret.2024.07.020
2024-07-29
Abstract:Purpose: To report one-year anatomical and functional real-world outcomes of treatment intensive neovascular age related macular degeneration (nAMD) patients switched to faricimab DESIGN: Retrospective multi-centre cohort study SUBJECTS: Consecutive nAMD patients on 4-weekly treatment interval with either ranibizumab or aflibercept 2mg in the last three visits within a treat and extend protocol (high treatment burden) prior to switch to faricimab at Moorfields Eye Hospital between 5/9/2022- 5/12/2022. Methods: Total number of nAMD patients switched to faricimab were identified from electronic medical records and those who met criteria of high treatment burden were included. Data collected included pre and post-switch visual acuity (VA), treatment intervals, length of follow-up, baseline macular morphology, changes in central subfield thickness (CST), macular fluid status and adverse events. Main outcome measures: VA, CST, presence of intraretinal fluid (IRF), subretinal fluid (SRF) and injection intervals over one-year following switch to faricimab. Results: A total of 130/ 286 (45.5%) eyes met inclusion criteria of being switched due to high treatment burden and 117 were included in analysis. Prior to switch to faricimab, these eyes received mean total number of injections of 33.4±19.6 over mean of 51.3±34.9 months. Mean number of injections in 12 months preceding switch was 10.1±1.6 and mean interval of the preceding three injections was 4.2±0.3 weeks. Mean VA, CST and percentage of patients with dry macula prior to switch were 66.0±11.9 ETDRS letters, 259.6±76.0μm and 18.3% respectively. Following switch, there was no statistical difference in mean VA after each visit and at 12 months. Mean CST statistically significantly reduced following the 3rd faricimab injection and at 12 months by 20.0μm (p=0.035) and 22.1μm (p=0.041) respectively. Mean treatment intervals increased to 6.9±2.3 weeks (p<0.005) at 12 months with 42.9% and 11.4% of patients being on ≥8 weekly and ≥12 weekly treatment intervals respectively. Conclusion: At 12 months, patients with nAMD with previous record of high treatment burden when switched to faricimab maintained visual acuities and improved anatomical outcomes on extended treatment intervals. Physician bias is inherent in these types of observational studies so a prospective randomised controlled trial is recommended to validate these findings.